Gastrointestinal stromal tumor
MONDO:0011719Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal (GI) tract, typically presenting in adults over the age of 40 (mean age 63), and only rarely in children, in various regions of the GI tract, most commonly the stomach or small intestine but also less commonly in the esophagus, appendix, rectum and colon. GISTs can be asymptomatic or present with various non-specific signs, depending on the location and size of tumor, such as loss of appetite, anemia, weight loss, fatigue, abdominal discomfort or fullness, nausea, vomiting, as well as an abdominal mass, blood in stool, and intestinal obstruction. GISTs can also be seen in familial syndromes such as Carney triad and neurofibromatosis type 1.
Also known as: GIST, Gastrointestinal Stromal Tumors, gastrointestinal stromal neoplasm, gastrointestinal stromal sarcoma, gastrointestinal stromal tumor, gastrointestinal stromal tumor (gist), gastrointestinal stromal tumor, familial, isolated cases, gastrointestinal stromal tumor, isolated cases
1541 clinical trials for this condition and its sub-types, 93 tagged with Gastrointestinal stromal tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for Drug-Resistant stomach cancer? sorafenib trial underway
Disease control OngoingThis phase 2 trial tests the drug sorafenib in 38 patients with gastrointestinal stromal tumor (GIST) that has worsened despite treatment with imatinib and sunitinib. Sorafenib works by blocking enzymes that help tumors grow and by cutting off blood supply to the cancer. The stud…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug targets rare sarcomas and GIST with genetic mutations
Disease control OngoingThis study tests a drug called rogaratinib in about 48 people with advanced sarcoma or a rare type of GIST that has certain genetic changes. The drug works by blocking proteins that help cancer cells grow. The goal is to see if it can shrink tumors or slow the disease, while moni…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for rare GIST mutations: regorafenib trial targets stubborn tumors
Disease control OngoingThis study tests whether the drug regorafenib can help control gastrointestinal stromal tumors (GIST) that have specific gene changes (KIT exon 17, 18, or 14, or SDHB deficiency) after imatinib stops working. It includes adults with measurable, unresectable tumors. The main goal …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New pill shows promise for tough stomach cancer in early trial
Disease control OngoingThis first-in-human study tests an experimental oral drug called IDRX-42 in 278 adults with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The main goals are to check safety, find the right dose, and see if the drug can shrink tu…
Phase 1 • Sponsor: IDRX, Inc., a wholly owned subsidiary of GSK, LLC • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New surgery aims to remove stomach tumors without major incisions
Disease control By invitation onlyThis study tests a new surgical method for removing non-cancerous or early cancerous growths (submucosal tumors) located where the stomach meets the esophagus. The technique combines two types of scopes (laparoscope and endoscope) with a special step to prepare the blood vessels …
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for GIST patients: ripretinib takes on sunitinib in major trial
Disease control OngoingThis phase 3 trial compares two targeted cancer pills, ripretinib and sunitinib, in about 450 people with advanced gastrointestinal stromal tumor (GIST) whose first treatment (imatinib) stopped working or caused side effects. The main goal is to see if ripretinib delays cancer gr…
Phase 3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New combo targets Hard-to-Treat stomach tumors
Disease control OngoingThis early-phase trial tests a new drug, pimitespib (TAS-116), combined with the standard drug imatinib in people with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to imatinib. The study aims to find the safest dose, check for side effects, and see…
Phase 1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for rare stomach cancer: drug combo targets tough mutations
Disease control OngoingThis study compares two drugs, ripretinib and sunitinib, in people with advanced gastrointestinal stromal tumors (GIST) that have specific genetic changes (KIT exon 11 plus 17/18 mutations) and have stopped responding to the first treatment, imatinib. About 54 participants will b…
Phase 3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug cocktail aims to tackle tough stomach cancer
Disease control OngoingThis study tests a combination of two drugs, MEK162 and imatinib (Gleevec), in people with advanced gastrointestinal stromal tumor (GIST). The first part finds the safest dose, and the second part checks how well the combo shrinks tumors. About 75 participants will take part, inc…
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for drug-resistant GIST: combo therapy targets stubborn tumors
Disease control OngoingThis study tests a new two-drug combination (bezuclastinib plus sunitinib) in 40 adults with advanced gastrointestinal stromal tumors (GIST) that grew while on sunitinib alone. The goal is to see if the combo can slow cancer progression and understand why some tumors resist treat…
Phase 2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Blood test may spot hidden GIST recurrence before scans do
Diagnosis PausedThis study is looking at whether a blood test that detects tiny traces of tumor DNA (called minimal residual disease, or MRD) can predict if a high-risk gastrointestinal stromal tumor (GIST) will return after surgery. The study will follow 66 patients who have had their tumor rem…
Sponsor: Peking University People's Hospital • Aim: Diagnosis
Last updated Aug 27, 2026 00:00 UTC
-
Home monitoring may keep cancer patients out of the ER
Symptom relief OngoingThis study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Taiwan study hunts for hidden genetic clues in rare stomach cancer
Knowledge-focused OngoingThis study looks at the genetic makeup of a rare stomach cancer called gastrointestinal stromal tumor (GIST) in patients whose tumors lack common mutations. Researchers will analyze tumor samples from 50 people in Taiwan to find other genetic changes that might be treatable. The …
Sponsor: National Health Research Institutes, Taiwan • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Experts unite to make cancer trial results easier to compare
Knowledge-focused OngoingThis study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC